PDF(Pubmed)
Abstract：
BACKGROUND: We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance.
METHODS: Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed.
RESULTS: We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively.
CONCLUSIONS: Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached.
METHODS: Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed.
RESULTS: We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively.
CONCLUSIONS: Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached.
摘要：
背景：我们评估了在Omicron占优势期间，sotrovimab与没有早期COVID-19治疗的高危COVID-19患者的有效性。
方法：使用伦敦西北部的Discover数据集进行回顾性队列研究。包括患者是非住院患者，年龄≥12岁，符合≥1个国家卫生服务机构sotrovimab治疗的最高风险标准。我们使用Cox比例风险模型比较了接受索特罗韦单抗治疗和未经治疗的患者28天COVID-19相关住院/死亡的HR。年龄,我们进行了肾脏疾病和Omicron亚变异亚组分析.
结果：我们包括599名sotrovimab治疗的患者和5191名未经治疗的患者。与未经治疗的患者相比，sotrovimab治疗组的COVID-19住院/死亡风险(HR0.50,95%CI0.24,1.06;p=0.07)和COVID-19住院风险(HR0.43,95%CI0.18,1.00;p=0.051)均较低;然而,没有达到统计学意义。在≥65岁和肾脏疾病亚组中，sotrovimab与COVID-19住院风险显著降低相关，89%(HR0.11，95%CI0.02，0.82；p=0.03)和82%(HR0.18，95%CI0.05，0.62；p=0.007)，分别。
结论：与未经治疗的患者相比，年龄≥65岁且患有肾脏疾病的sotrovimab治疗患者的COVID-19住院风险明显较低。总的来说,sotrovimab治疗的患者的住院风险也较低，但没有达到统计学意义。
方法：使用伦敦西北部的Discover数据集进行回顾性队列研究。包括患者是非住院患者，年龄≥12岁，符合≥1个国家卫生服务机构sotrovimab治疗的最高风险标准。我们使用Cox比例风险模型比较了接受索特罗韦单抗治疗和未经治疗的患者28天COVID-19相关住院/死亡的HR。年龄,我们进行了肾脏疾病和Omicron亚变异亚组分析.
结果：我们包括599名sotrovimab治疗的患者和5191名未经治疗的患者。与未经治疗的患者相比，sotrovimab治疗组的COVID-19住院/死亡风险(HR0.50,95%CI0.24,1.06;p=0.07)和COVID-19住院风险(HR0.43,95%CI0.18,1.00;p=0.051)均较低;然而,没有达到统计学意义。在≥65岁和肾脏疾病亚组中，sotrovimab与COVID-19住院风险显著降低相关，89%(HR0.11，95%CI0.02，0.82；p=0.03)和82%(HR0.18，95%CI0.05，0.62；p=0.007)，分别。
结论：与未经治疗的患者相比，年龄≥65岁且患有肾脏疾病的sotrovimab治疗患者的COVID-19住院风险明显较低。总的来说,sotrovimab治疗的患者的住院风险也较低，但没有达到统计学意义。
